Vaccitech (NASDAQ: VACC)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-11 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.310 | 0.070 | 0.3800 | ||||
REV | 3.570M | 15.018M | 11.448M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Vaccitech (NASDAQ: VACC) through any online brokerage.
Other companies in Vaccitech’s space includes: Macrogenics (NASDAQ:MGNX), AVEO Pharmaceuticals (NASDAQ:AVEO), Impel Pharmaceuticals (NASDAQ:IMPL), Vaxxinity (NASDAQ:VAXX) and Inozyme Pharma (NASDAQ:INZY).
The latest price target for Vaccitech (NASDAQ: VACC) was reported by Morgan Stanley on Tuesday, May 17, 2022. The analyst firm set a price target for 19.00 expecting VACC to rise to within 12 months (a possible 271.82% upside). 3 analyst firms have reported ratings in the last year.
The stock price for Vaccitech (NASDAQ: VACC) is $5.11 last updated June 29, 2022, 8:00 PM UTC.
There are no upcoming dividends for Vaccitech.
Vaccitech’s Q2 earnings are confirmed for Thursday, August 11, 2022.
There is no upcoming split for Vaccitech.
Vaccitech is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.